<!DOCTYPE html>

<html lang="en">
<head>
<meta charset="utf-8"/>
<title>article123</title>
<style>
        body {
            font-family: Arial, sans-serif;
            margin: 0;
            padding: 0;
            background-color: #f3f3f3;
        }
        .container {
            max-width: 800px;
            margin: auto;
            background: #fff;
            padding: 20px;
            box-shadow: 0 0 10px rgba(0, 0, 0, 0.1);
        }
        h1, h2 {
            color: #333;
        }
        p {
            line-height: 1.6;
        }
        a {
            text-decoration: none;
            color: #5a5a5a;
        }
        a:hover {
            color: #000;
        }
    </style>
</head>
<body>
<div class="container"><p><a href="../index.html">Back to Index</a></p><li><a href="https://www.wikijournalclub.org/wiki/MADIT-CRT" style="display:block; margin-bottom:10px;">MADIT-CRT Original</a></li>
<h2><strong>MADIT-CRT</strong></h2>
<div class="container">
<h2><strong></strong></h2>
<div class="container">
<div class="container">
<h2><strong></strong></h2>
<h2><strong></strong></h2>

    "Cardiac-Resynchronization Therapy for the Prevention of Heart-Failure Events".<br/>
<br/>
The New England Journal of Medicine. 2009. 361(14):1329-1338.<br/>
PubMed•Full text•PDF<br/>
<br/>
<h2><strong>Contents</strong></h2><br/>
1 Clinical Question<br/>
2 Bottom Line<br/>
3 Major Points<br/>
4 Guidelines<br/>
5 Design<br/>
6 Population<br/>
6.1 Inclusion Criteria<br/>
6.2 Exclusion Criteria<br/>
6.3 Baseline Characteristics<br/>
7 Interventions<br/>
8 Outcomes<br/>
8.1 Primary Outcome<br/>
8.2 Secondary Outcomes<br/>
9 Funding<br/>
10 Further Reading<br/>
<br/>
<h2><strong>Clinical Question</strong></h2><br/>
Does cardiac-resynchronization therapy (CRT) with biventricular pacing reduce the risk of death or heart-failure events in patients with mild cardiac symptoms, a reduced ejection fraction, and a wide QRS complex?<br/>
<br/>
<h2><strong>Bottom Line</strong></h2><br/>
CRT combined with an implantable cardioverter–defibrillator (ICD) decreased the risk of heart-failure events in relatively asymptomatic patients with a low ejection fraction and wide QRS complex.<br/>
<br/>
<h2><strong>Major Points</strong></h2><br/><br/>
<br/>
<h2><strong>Guidelines</strong></h2><br/>
The 2008 guidelines for implantation of cardiac devices recommend CRT as a class I indication for patients with a left ventricular ejection fraction of 35% or less, a QRS duration of 120 msec or more, and sinus rhythm who have NYHA functional class III or ambulatory class IV heart-failure symptoms.<br/>
<br/>
<h2><strong>Design</strong></h2><br/>
Multicenter, randomized, controlled trial<br/>
N=1,820<br/>
CRT-ICD (n=1,089)<br/>
ICD alone (n=731)<br/>
Setting: 110 hospital centers<br/>
Enrollment: 2004-2008<br/>
Mean follow-up: 2.4 years<br/>
Analysis: Intention-to-treat<br/>
Primary outcome: Death from any cause or a nonfatal heart-failure event<br/>
<br/>
<h2><strong>Population</strong></h2><br/>
Inclusion Criteria: NYHA class I (ischemic cardiomyopathy) or class II (ischemic or nonischemic cardiomyopathy), ejection fraction of ≤30%, QRS duration ≥130 msec, sinus rhythm.<br/>
Exclusion Criteria: Existing or planned CRT, recent MI or cardiac intervention, atrial fibrillation, and other criteria.<br/>
Baseline Characteristics: Similar across groups.<br/>
<br/>
<h2><strong>Interventions</strong></h2><br/>
Patients were randomly assigned to receive CRT with an ICD (CRT-ICD group) or an ICD alone (ICD-only group).<br/>
<br/>
<h2><strong>Outcomes</strong></h2><br/>
Primary Outcome: Risk reduction of 34% for death or nonfatal heart-failure events in the CRT-ICD group compared to the ICD-only group (hazard ratio, 0.66; 95% confidence interval, 0.52 to 0.84; P=0.001).<br/>
Secondary Outcomes: Significant reduction in left ventricular volumes and improvement in ejection fraction in the CRT-ICD group.<br/>
<br/>
<h2><strong>Funding</strong></h2><br/>
Supported by a research grant from Boston Scientific to the University of Rochester.<br/>
<br/>
<h2><strong>Further Reading</strong></h2><br/>
Full text available on the New England Journal of Medicine website.
    <p></p>
</div>
</div>
</div>
</div>
</body>
</html>
